News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Innova Biosciences Appoints Two New Board Members



7/7/2009 12:14:09 PM

Innova Biosciences (Cambridge, UK), inventor of the World’s easiest to use conjugation kit called Lightning-Link™, is pleased to announce the appointment of two non-executive directors Tim Bernard and Lucy Block to the Board.

Tim has 24 years experience of executive level leadership, strategic development and international sales within the life science sector. Formerly Managing Director of the antibody company AbD Serotec, Tim was a key contributor in the set up, growth and eventual sale of the business, strategically growing the operation from a £300K turnover to its sale for £20m to the Morphosys group in 2006. Since leaving AbD Serotec, Tim has worked with a series of SME Biotech companies (such as Oxford Expression Technologies, Everest Biotech and DB Biotech) to realise their full potential.

Lucy has a wealth of experience in developing start-up to early stage biotechnology companies. Before becoming a life science consultant, Lucy was an Investment Manager at Cambridge Research and Innovation Ltd (CRIL) for 10 years. At CRIL Lucy was instrumental in growing and nurturing several biotech start-ups including Phico, Ashby Biosystems, and Endocrine Pharmaceuticals to name a few. Lucy also has experience of patenting and IP portfolio management.

Commenting on the announcement Dr Nick Gee, CEO of Innova Biosciences ‘I am delighted that Lucy and Tim have agreed to join the Board of Directors. The appointments significantly strengthen our capabilities in the areas of sales, financial management and strategic planning, and will help the company to maintain its current high rate of growth’

About the company: Innova Biosciences is a growing, dynamic business, based in Cambridge, UK. At the core of Innova’s business is the Lightning-Link™, an innovative technology that simplifies production of bioconjugates for use in R&D applications, drug discovery and diagnostics. The expanding Lightning-Link™ portfolio currently consists of 44 individual products and is sold to research laboratories in over 30 countries around the world.


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES